Condition
Ocular Graft vs Host Disease
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
100.0%
3 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 3 (1)
Trial Status
Terminated3
Clinical Trials (3)
Showing 3 of 3 trials
NCT03591874Phase 3Terminated
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
NCT02702518Phase 1TerminatedPrimary
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
NCT02975557Phase 1Terminated
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Showing all 3 trials